Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CDA | P32320 | 1/20 | 0.39 |
| ▸ | ATG7 | O95352 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367297 | 0.86 | L3MBTL1 (0.40) | ADORA1ADORA3ADORA2AADORA2BL3MBTL1 | |
| SCHEMBL5911972 | 0.84 | ADORA3 (0.41) | ADORA1ADORA3ADORA2AADORA2BMAPT | |
| SCHEMBL5911964 | 0.84 | ADORA3 (0.41) | ADORA1ADORA3ADORA2AADORA2BMAPT | |
| SCHEMBL5911675 | 0.82 | MAPT (0.56) | ADORA3MAPTCDA | |
| SCHEMBL11070054 | 0.82 | MAPT (0.56) | ADORA3MAPTCDA | |
| SCHEMBL12071279 | 0.82 | MAPT (0.56) | ADORA3MAPTCDA | |
| SCHEMBL5911672 | 0.82 | MAPT (0.56) | ADORA3MAPTCDA | |
| SCHEMBL5911861 | 0.82 | MAPT (0.56) | ADORA3MAPTCDA | |
| SCHEMBL5911868 | 0.82 | MAPT (0.56) | ADORA3MAPTCDA | |
| SCHEMBL365948 | 0.81 | MAPT (0.43) | ADORA1ADORA3ADORA2AADORA2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | ADORA1 3487/4885ADORA3 2690/4885ADORA2A 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.